Rosalind Capital Partners

Rosalind Advisors, also known as Rosalind Capital, is a Toronto-based investment firm founded in 2006, operating as an event-driven equity hedge fund at the intersection of science and finance within the life sciences sector. The firm manages several biotech-oriented funds, including Rosalind Capital Partners, Rosalind Master Fund, and Rosalind Offshore Fund, deploying long/short equity strategies to capitalize on consistent market inefficiencies and arbitrage opportunities within biotech public markets. Its sector focus centers on biotechnology and life sciences, spanning oncology, ophthalmology, and dermatology. Notable holdings and investments include Delcath Systems, Savara, Fennec Pharmaceuticals, Replimune Group, ArriVent BioPharma, Biofrontera, and Kiora Pharmaceuticals. Rosalind's investment approach favors concentrated positions in public biotech securities backed by deep scientific and clinical understanding, rather than broad diversification. Its criteria favor companies demonstrating strong growth potential and innovation, primarily across North American markets.